Impact of glucagon-like peptide-1 receptor agonists with guideline-directed medical therapy in patients with heart failure with reduced ejection fraction and type 2 diabetes
Main finding · All-cause deathResult — go to the resultHazard ratio 0.71 95 % CI 0.62–0.83Authors' conclusion
In patients with HFrEF and T2D, all of GDMTs with GLP-1 RAs were associated with a lower risk of all-cause death than all of GDMTs without GLP-1 RAs.
Study context
- Population
- Patients with heart failure with reduced ejection fraction (HFrEF) and T2D, 2018–2023 (TriNetX); before matching 3,379 received guideline-directed medical therapy (GDMT) with GLP-1 RA and 14,712 withoutmatched cohort
- Participants
- 3,158 vs 3,158
- Exposure
- GDMT with GLP-1 RA vs GDMT without GLP-1 RA
- GDMT + GLP-1 RAn = 3,158
- GDMT without GLP-1 RAn = 3,158reference
- Outcome
- All-cause death
- Follow-up
- 18 months
Methodological detailspropensity-score matched, TriNetX platform
- Propensity-score matched
- TriNetX platform
Main finding
As reported in the abstract
Hazard ratio
0.71
95 % CI 0.62–0.83
By group
GDMT + GLP-1 RAvs GDMT without GLP-1 RA
HR 0.71 (95 % CI 0.62–0.83)
Observational data: associations, not effects.
Secondary outcomes
%
| Outcome | GDMT + GLP-1 RA | GDMT without GLP-1 RA | HR (95 % CI) | |
|---|---|---|---|---|
| HospitalizationDid not differ significantly | 63.7 | 60.1 | 1.05 (0.98–1.12) | |
| 0.512Hazard ratio (log scale) |
Original publication
Impact of glucagon-like peptide-1 receptor agonists with guideline-directed medical therapy in patients with heart failure with reduced ejection fraction and type 2 diabetes. Diabetes Res Clin Pract. Published 1 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →